drugset / Trial / NCT06115005

Treatment of Challenging Macular Holes Using Plasma Rich in Growth Factors

NCT06115005

Phase 2 Unknown 40 enrolled Minia University
NaSingle-groupQuadruple-blindTreatment

Summary

Aim of the Study:To report the structural and visual outcomes of plasma rich in growth factors in closure of challenging macular holes

Timeline

Start
2022-06-01
Primary completion
2023-12-31
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Plasma rich in growth factors Other / unclassified

Indications